What Is AOD-9604?

Ng et al. demonstrate AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 or glucose tolerance.

Heffernan et al.: Pooled analysis of 6 RCTs showing AOD-9604 is well-tolerated with a safety profile similar to placebo despite limited efficacy signals.

12-week Phase IIb trial: 1mg/day AOD-9604 produced 2.6 kg weight loss vs 0.8 kg placebo, with reductions in abdominal fat and improved lipid profiles.

A 2026 review found that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, though rigorous human safety data remain scarce. The study investigated the pharmacological mechanisms and regulatory status of various sports medicine peptides.

Therapeutic peptides such as BPC-157 and TB-500 were found to modulate key molecular pathways influencing tissue regeneration and inflammation resolution in a 2026 review. The study demonstrated that while preclinical mechanistic data is promising for orthopaedic applications, clinical trials remain lacking.

A 2018 study in diet-induced obese mice demonstrated that PS10, a novel pyruvate dehydrogenase kinase inhibitor, stimulated myocardial carbohydrate oxidation and improved glucose tolerance. Researchers found that PS10 achieved these effects without increasing lactate production, unlike the classic inhibitor dichloroacetate.

A 2016 study demonstrated a highly sensitive screening method for detecting prohibited peptides under 2 kDa, such as GHRPs and TB-500, directly from urine. The liquid chromatography and mass spectrometry assay successfully identified peptide administration in human elimination samples, improving anti-doping control measures.

In a 2015 study, researchers found that intra-articular injections of AOD9604 enhanced cartilage regeneration in a rabbit model of osteoarthritis. Furthermore, the study demonstrated that combining AOD9604 with hyaluronic acid was more effective at reducing cartilage degeneration than either treatment alone.

A 2017 review demonstrated that mass spectrometry has become an indispensable tool in modern sports drug testing. The paper detailed its critical role in detecting diverse substances, including peptidic drugs, anabolic agents, and nucleotide-derived therapeutics.

A 2014 review found that advanced mass spectrometric and immunological methods can successfully detect the misuse of various peptidic drugs, including TB-500 and CJC-1295, in sports doping. However, researchers noted a gap remains between technical capabilities and routine analytical practice.

A 2015 in vitro study demonstrated a validated extraction method for detecting AOD9604 in urine and identified six potential metabolites. Researchers found that one specific metabolite is significantly more stable than the parent compound, potentially increasing the detection window.

A 2014 review detailed analytical strategies, including chromatographic-mass spectrometric methods, for detecting emerging performance-enhancing peptides like TB-500 and AOD-9604 in human doping controls. The study highlighted the specific physicochemical requirements for identifying these non-approved drugs in blood and urine.

A 2006 review highlighted that several anti-obesity drugs were in clinical development, including the human growth hormone fragment AOD-9604, which was investigated for its ability to increase adipose tissue breakdown. The study outlined various emerging therapies targeting satiety, fat absorption, and metabolism.

A 2005 bibliography documented recent clinical trial data for numerous pharmacological agents, including the peptide AOD-9604, serving as a reference guide for ongoing drug discovery and development.

AOD-9604 was actively being developed and investigated for the potential treatment of obesity, according to a 2004 review. The report demonstrated that phase IIa clinical trials were already underway to evaluate the peptide's metabolic effects.

A 2003 bibliography documented ongoing clinical trial data for numerous pharmacological compounds, including AOD-9604 and exenatide, utilizing the Prous Science Integrity database. The publication provided a comprehensive reference guide for recent drug discovery and development efforts across various therapeutic categories.

A 2003 bibliography demonstrated the breadth of ongoing pharmaceutical research by indexing recent clinical trial data for numerous drugs and peptides, including AOD-9604 and epithalon. The publication served as a comprehensive guide to contemporary drug discovery and development.

A 2001 study in obese mice demonstrated that AOD9604 and human growth hormone reduced body weight and fat while increasing beta-3 adrenergic receptor expression. Researchers found that although these compounds enhance lipolytic sensitivity, their direct lipolytic actions are not solely mediated through this receptor.